LGG vs Other Probiotics: Why Clinical Evidence Still Points to LGG

Walk down any supplement aisle or browse any probiotic category online and you will encounter a lot of impressive-sounding claims attached to a lot of different bacterial strains. Lactobacillus acidophilus. Bifidobacterium longum. Saccharomyces boulardii. Multi-strain blends with 50 billion CFU and 15 different species. The marketing all sounds compelling.

But probiotics are not interchangeable. A strain is not a probiotic category the way a vitamin is a nutrient category. Each strain has its own research record, its own mechanisms, its own clinical application data, and its own survival and colonization characteristics. Lumping them together is like saying "all vegetables are the same because they're all plants."

Lactobacillus rhamnosus GG, universally abbreviated as LGG, stands out from this crowded field for one reason above all others: it has more clinical research than any other probiotic strain in history. With over 1,000 published studies, LGG has been tested in conditions ranging from antibiotic-associated diarrhea to irritable bowel syndrome to immune function across populations from infants to the elderly. No other probiotic strain comes close to this body of evidence.

This article compares LGG directly to the three other most commonly used probiotic strains and categories, with an honest look at where the evidence sits for each.

What Makes LGG Distinctive Before Any Comparison

LGG was isolated in 1985 by Sherwood Gorbach and Barry Goldin at Tufts University (the "GG" in the name stands for Gorbach-Goldin). It was one of the first probiotic strains to be rigorously characterized and commercially developed, which gave it a substantial head start in clinical research.

Several biological properties help explain why LGG has performed consistently across research settings:

Gut adhesion is a prerequisite for meaningful probiotic activity. LGG possesses specialized pili (hair-like surface structures) that allow it to adhere to human intestinal mucosa more strongly than most other lactobacillus strains. This adhesion extends LGG's residence time in the gut, giving it more time to interact with immune cells and intestinal epithelium.

Acid and bile resistance is critical for any orally administered probiotic to survive gastric transit and reach the colon alive. LGG has demonstrated excellent survival in the hostile gastric environment, with studies showing meaningful CFU counts reaching the colon after oral administration in encapsulated form.

Mucus layer interaction goes beyond simple adhesion. LGG's pili bind specifically to mucin glycoproteins in the gut mucus layer, positioning the bacteria close to the epithelial surface where immune interaction is most relevant.

Safety record across decades of clinical use and research in vulnerable populations, including preterm infants and immunocompromised adults, with an established safety profile that most newer strains cannot match.

LGG vs Lactobacillus Acidophilus

Lactobacillus acidophilus is probably the most commonly sold probiotic strain and has been a fixture of the probiotic supplement industry for decades. It is a well-studied lactobacillus with a legitimate research base, particularly for vaginal health, certain diarrheal conditions, and lactose intolerance.

Where does it sit relative to LGG?

L. acidophilus has substantially less clinical research than LGG, with roughly a quarter of the published study volume. For specific applications like vaginal health and certain bacterial infections, L. acidophilus may be the more relevant strain because it naturally colonizes the vaginal tract and has been studied specifically in that context. For gastrointestinal applications, the clinical evidence base for LGG is more extensive and more consistent.

A key difference in gut adhesion: L. acidophilus adheres primarily to the small intestine, while LGG colonizes both the small and large intestine more broadly. For conditions involving the colon, which includes IBS, inflammatory bowel disease, and antibiotic-associated diarrhea, LGG's broader colonization range is potentially advantageous.

A 2020 meta-analysis in Nutrients comparing various lactobacillus strains for prevention of antibiotic-associated diarrhea found LGG among the highest-ranked strains for this indication, with more consistent effect sizes across included trials than L. acidophilus-containing interventions.

In multi-strain products containing both LGG and L. acidophilus, the strains may compete for adhesion sites, which is one argument for single-strain supplementation with a well-characterized strain over blends where inter-strain interactions are poorly understood.

LGG vs Bifidobacterium Strains

Bifidobacterium is a genus of anaerobic bacteria that colonize the colon preferentially. The most commonly supplemented species include Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium bifidum. Collectively, Bifidobacterium species are important players in infant gut development and adult colon health.

The comparison between LGG and Bifidobacterium is in some ways a comparison between different ecological niches. LGG is primarily a small intestine colonizer with broad activity, while Bifidobacterium species are primarily colon colonizers with particular relevance to the microbiome composition of the distal gut.

Bifidobacterium infantis 35624 (now reclassified as Lactobacillus longum) has specific clinical research in IBS, with trials showing reductions in bloating and abdominal pain in IBS patients. This is meaningful and well-supported data. However, the body of evidence for Bifidobacterium species as a class remains smaller and more fragmented than LGG's unified research record.

Bifidobacterium species also tend to be more fragile in terms of gastric transit and shelf stability. Many Bifidobacterium strains require specific encapsulation or refrigeration to deliver viable counts at the intestine, whereas LGG's established acid resistance makes it more forgiving in terms of formulation and storage conditions.

For conditions like antibiotic-associated diarrhea and respiratory infections, LGG has a substantially stronger and more replicated clinical evidence base than any individual Bifidobacterium strain. For conditions primarily affecting the colon's microbial ecology, Bifidobacterium strains may be more directly relevant. The two are not strict competitors; they operate in different parts of the gut and may be complementary.

LGG vs Saccharomyces Boulardii

Saccharomyces boulardii is fundamentally different from LGG: it is a yeast, not a bacterium. This distinction matters for several reasons. S. boulardii is not affected by antibiotics (which target bacteria), making it the preferred probiotic choice during and immediately after antibiotic courses when bacterial probiotics may be suppressed. It also cannot colonize the gut permanently, exerting its effects transiently during supplementation.

S. boulardii has strong clinical evidence for specific applications. A Cochrane review found good evidence for S. boulardii in prevention of antibiotic-associated diarrhea, particularly Clostridioides difficile-associated diarrhea. For traveler's diarrhea, S. boulardii also has solid supporting evidence.

However, LGG competes directly with S. boulardii even for antibiotic-associated diarrhea, where multiple trials and meta-analyses show comparable or superior performance for LGG depending on the population studied. A 2019 systematic review in The Lancet Gastroenterology and Hepatology identified both LGG and S. boulardii as among the highest-evidence probiotics for antibiotic-associated diarrhea prevention, with LGG showing particular strength in pediatric populations.

For individuals with yeast sensitivities or those taking antifungal medications, S. boulardii is not appropriate. LGG, as a bacterial strain, is unaffected by antifungal drugs and represents the safer choice in those contexts.

The key practical difference: S. boulardii is the preferred choice when antibiotics are actively being taken, because antibiotics cannot kill it. LGG is typically recommended before, alongside (at a different time of day), or after antibiotic courses. Both have roles, but for general probiotic supplementation outside of antibiotic use, LGG's broader clinical application record gives it a wider range of supported uses.

The Research Volume Advantage

The practical significance of LGG having over 1,000 published studies cannot be overstated. In clinical research, replication is everything. A single positive study for a probiotic strain means relatively little. A consistent pattern across dozens of independent studies in different populations and settings is a much stronger signal.

LGG has been tested in:

• Antibiotic-associated diarrhea prevention (multiple Cochrane reviews and meta-analyses with positive findings)
• Acute infectious diarrhea in children (European Society for Pediatric Gastroenterology recommendations)
• Irritable bowel syndrome (multiple randomized controlled trials)
• Respiratory tract infections in children and adults
• Atopic dermatitis prevention in infants
• Immune modulation across multiple populations
• C. difficile recurrence prevention
• Inflammatory bowel disease adjunct therapy

This breadth of clinical application, all built on the same strain with the same mechanism of action, is unprecedented in probiotic research. No other strain has this combination of volume and breadth. Our LGG probiotic benefits guide covers the research across these categories in depth.

Choosing Between Strains in Practice

The honest guidance here is not "LGG is always better than every other probiotic" but rather "LGG has the strongest and broadest evidence base, which makes it the most defensible choice for general probiotic supplementation."

If you have a specific condition with strong evidence for a particular strain (S. boulardii for C. diff prevention during antibiotics; B. infantis 35624 for IBS-specific symptom relief; L. acidophilus for vaginal health), using that strain makes sense. Probiotics are not one-size-fits-all.

For general gut health, immune support, and the kind of broad digestive benefits most people are seeking from a probiotic, LGG's research depth makes it the most evidence-backed option on the market. When you do not have a specific condition requiring a specific strain, defaulting to the most-studied strain with the best-characterized safety profile is rational.

For IBS-specific considerations, our LGG for IBS guide covers the clinical trials in detail.

What to Look for in an LGG Supplement

Not all LGG supplements are equivalent. Key factors include CFU count (meaningful doses in clinical research typically range from 5 billion to 40 billion CFU), capsule integrity to ensure survival through gastric transit, and absence of unnecessary fillers that can affect viability.

Wise Choice's LGG probiotic supplement provides 30 billion CFU per capsule across 90 capsules, placing the dose solidly within the range used in positive clinical research. For a broader review of how to evaluate LGG products, see our guide to the best LGG probiotic supplements.

Conclusion

LGG leads the probiotic field in clinical evidence for one reason: it has been studied more rigorously, more repeatedly, and across more conditions than any competing strain. The biological properties that underlie its performance, particularly its acid resistance, adhesion pili, and colonization breadth, give the research results a mechanistic foundation that makes the evidence more interpretable and more trustworthy.

L. acidophilus, Bifidobacterium strains, and S. boulardii all have legitimate clinical applications in specific contexts. But for general probiotic supplementation backed by the deepest evidence base in the field, LGG remains the gold standard. Wise Choice's 30 billion CFU LGG supplement gives you that strain at a clinically meaningful dose.

Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.